Last reviewed · How we verify
NCT06854939: MRDSEEKER
A Prospective Study Investigating the Relationship Between Minimal Residual Disease Detection, Monitoring Frequency, and Prognosis in Non-small Cell Lung Cancer Patients Eligible for Curative Treatment.
trial in NSCLC, Stage I, II, III in 350 participants. Not yet recruiting.
30 September 2026
Quick facts
| Lead sponsor | National Cancer Center, Japan |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 350 |
| Start date | 1 March 2025 |
| Primary completion | 30 September 2026 |
| Estimated completion | 30 September 2029 |
| Sites | 1 location across Japan |
Conditions studied
- NSCLC, Stage I, II, III — all drugs for NSCLC, Stage I, II, III →
Sponsor
National Cancer Center, Japan
Who can join
18 and older, any sex, with NSCLC, Stage I, II, III. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Adding immune checkpoint inhibitors or molecularly targeted drugs as adjuvant therapy to curative treatments-such as surgery or chemoradiotherapy-for stage I-III non-small cell lung cancer (NSCLC) has been established as a standard of care and has improved treatment outcomes. However, there is currently no adequate method to determine which patients should receive these adjuvant therapies. Identifying those with a good prognosis without adjuvant therapy could reduce the risk of adverse events, lessen the burden of clinic visits, and reduce healthcare costs. Among various approaches, ctDNA-based MRD (minimal residual disease) analysis is highly anticipated and has already been introduced into clinical practice for hematologic malignancies. However, solid tumors' development as a companion diagnostic has been limited, and regulatory approval is mainly being considered based on performance evaluation data. In this study, we will conduct a performance evaluation of MRD analysis using Signatera™ in patients with stage I-III NSCLC while also collecting other prognostic factors based on clinicopathological information and survival data.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
[MRD Testing in Lung Cancer-Latest Insights and Developments].
Karasaki T, Horinouchi H. · · 2025 · cited 1× · PMID 40563149
Verify or expand the search:
- PubMed search for NCT06854939
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other National Cancer Center, Japan trials
Trials by the same sponsor.
- NCT07347314 — Enfortumab Vedotin in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-based Combi · Phase 2 · recruiting
- NCT06673628 — Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma Patients · Phase 2 · recruiting
- NCT05832827 — First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Art · Phase 2 · recruiting
- NCT06159478 — Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume) · Phase 2 · recruiting
- NCT05433753 — Asian Multicenter Prospective Study in HER2 Positive Early Breast Cancer for Detecting MRD by ctDNA;HARMONY Study · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06854939 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Cancer Center, Japan
- Last refreshed: 3 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06854939.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing